Convalescent Plasma Therapy in Immunocompromised Patients Infected With the BA.1 or BA.2 Omicron SARS-CoV-2.
COVID-19
Omicron variant
SARS-CoV-2
convalescent plasma
immunocompromised
Journal
Influenza and other respiratory viruses
ISSN: 1750-2659
Titre abrégé: Influenza Other Respir Viruses
Pays: England
ID NLM: 101304007
Informations de publication
Date de publication:
Mar 2024
Mar 2024
Historique:
revised:
07
02
2024
received:
03
03
2023
accepted:
08
02
2024
medline:
19
3
2024
pubmed:
19
3
2024
entrez:
19
3
2024
Statut:
ppublish
Résumé
The emergence of SARS-CoV-2 Omicron variant has led to a complete reconfiguration of the therapeutic landscape, with all monoclonal antibodies having lost any neutralization activity. We report here a case series of 75 immunocompromised patients infected by the Omicron variant who benefited from COVID-19 convalescent plasma (CCP). At Day 28, the overall survival was 76% (95% CI 67-86) with no significant difference in the clinical outcome between patients with hematological malignancies, solid organ transplantation or autoimmune diseases. No safety concern was reported during the course of the study. These results showed that CCP is well tolerated and represents a treatment option for immunocompromised patients who remain highly impacted by the COVID19 epidemic.
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
e13272Informations de copyright
© 2024 The Authors. Influenza and Other Respiratory Viruses published by John Wiley & Sons Ltd.
Références
F. Baron, L. Canti, K. K. Ariën, et al., “Insights From Early Clinical Trials Assessing Response to mRNA SARS-CoV-2 Vaccination in Immunocompromised Patients,” Frontiers in Immunology 13 (2022): 827242.
A. Gupta, Y. Gonzalez-Rojas, E. Juarez, et al., “Early Treatment for Covid-19 with SARS-CoV-2 Neutralizing Antibody Sotrovimab,” The New England Journal of Medicine 385 (2021): 1941-1950.
M. J. Levin, A. Ustianowski, S. de Wit, et al., “Intramuscular AZD7442 (Tixagevimab-Cilgavimab) for Prevention of Covid-19,” New England Journal of Medicine 386 (2022): 2188-2200.
D. Planas, N. Saunders, P. Maes, et al., “Considerable Escape of SARS-CoV-2 Omicron to Antibody Neutralization,” Nature 602 (2022): 671-675.
D. J. Sullivan, K. A. Gebo, S. Shoham, et al., “Early Outpatient Treatment for Covid-19 with Convalescent Plasma,” The New England Journal of Medicine 386 (2022): 1700-1711.
M. A. Thompson, J. P. Henderson, P. K. Shah, et al., “Association of Convalescent Plasma Therapy With Survival in Patients With Hematologic Cancers and COVID-19,” JAMA Oncology 7 (2021): 1167-1175, https://doi.org/10.1001/jamaoncol.2021.1799
T. Hueso, A. S. Godron, E. Lanoy, et al., “Convalescent Plasma Improves Overall Survival in Patients With B-Cell Lymphoid Malignancy and COVID-19: A Longitudinal Cohort and Propensity Score Analysis,” Leukemia 36 (2022): 1025-1034.
S. Feng, D. J. Phillips, T. White, et al., “Correlates of Protection Against Symptomatic and Asymptomatic SARS-CoV-2 Infection,” Nature Medicine 27 (2021): 2032-2040.
WHO Working Group on the Clinical Characterisation and Management of COVID-19 infection, “A Minimal Common Outcome Measure Set for COVID-19 Clinical Research,” The Lancet Infectious Diseases 20 (2020): e192-e197.
P. Gallian, A. Amroun, S. Laperche, et al., “Reduced Neutralizing Antibody Potency of COVID-19 Convalescent Vaccinated Plasma Against SARS-CoV-2 Omicron Variant,” Vox Sanguinis 117 (2022): 971-975.
O. Blennow, J. Salmanton-García, P. Nowak, et al., “Outcome of Infection With Omicron SARS-CoV-2 Variant in Patients With Hematological Malignancies: An EPICOVIDEHA Survey Report,” American Journal of Hematology 97 (2022): E312-E317.
J. Lang-Meli, J. Fuchs, P. Mathé, et al., “Case Series: Convalescent Plasma Therapy for Patients With COVID-19 and Primary Antibody Deficiency,” Journal of Clinical Immunology 42 (2022): 253-265.
F. Rahman, S. T. H. Liu, S. Taimur, et al., “Treatment With Convalescent Plasma in Solid Organ Transplant Recipients With COVID-19: Experience at Large Transplant Center in New York City,” Clinical Transplantation 34 (2020): e14089.
A. Gupta, V. B. Kute, H. V. Patel, et al., “Feasibility of Convalescent Plasma Therapy in Kidney Transplant Recipients With Severe COVID-19: A Single-Center Prospective Cohort Study,” Experimental and Clinical Transplantation 19 (2021): 304-309.
T. Hueso, C. Pouderoux, H. Péré, et al., “Convalescent Plasma Therapy for B-Cell-Depleted Patients With Protracted COVID-19,” Blood 136 (2020): 2290-2295.
L. Plaçais, Q. Richier, N. Noël, K. Lacombe, X. Mariette, and O. Hermine, “Immune Interventions in COVID-19: A Matter of Time?” Mucosal Immunology 15 (2021): 198-210, https://doi.org/10.1038/s41385-021-00464-w